-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34

Benzinga·11/05/2026 15:00:18
Listen to the news
Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Overweight and raises the price target from $31 to $34.